Volition signs global supply agreement for Nu.Q Vet Cancer Test

Volition is a multinational epigenetics company that applies its Nucleosomics platform through its subsidiaries to develop simple, easy-to-use, cost-effective blood tests to help diagnose and monitor a range of life-altering diseases, including some cancers and diseases associated with NETosis such as sepsis and COVID-19. Early diagnosis and monitoring have the potential not only to prolong the life of patients but also to improve their quality of life. The tests are based on the science of Nucleosomics, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid – an indication that disease is present. Volition is primarily focused on human diagnostics and monitoring but also has a subsidiary focused on animal diagnostics and monitoring.

In this video, we hear from Cameron Reynolds, president and chief executive officer of Volition, Dr Tom Butera, chief executive officer of Volition Veterinary, Gael Forterre, chief commercial officer of Volition, and Dr Heather Wilson-Robles, chief medical officer of Volition Veterinary, who discuss signing a global supply agreement with a market leader in pet healthcare (‘the company’). Through the agreement, the company is engaged as a worldwide provider of the Nu.Q Vet Cancer Test through its reference laboratory network for cancer indications in animal health.